- Featured Product
- KD/KO Validated
TGFBI / BIGH3 Monoclonal antibody
TGFBI / BIGH3 Monoclonal Antibody for IF, IHC, IP, WB, ELISA
Cat no : 60007-1-Ig
Validation Data Gallery
|Positive WB detected in||human kidney tissue|
|Positive IP detected in||HeLa cells|
|Positive IHC detected in||human colon tissue, human skin cancer tissue, human colon cancer tissue, human placenta tissue, human kidney tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||human colon cancer tissue|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:500-1:2000|
|Immunofluorescence (IF)||IF : 1:200-1:800|
|Sample-dependent, check data in validation data gallery|
60007-1-Ig targets TGFBI / BIGH3 in WB, IP, IHC, IF, ELISA applications and shows reactivity with human samples.
|Cited Reactivity||human, mouse|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||TGFBI / BIGH3 fusion protein Ag0241|
|Full Name||transforming growth factor, beta-induced, 68kDa|
|Calculated molecular weight||683 aa, 75 kDa|
|Observed molecular weight||68 kDa|
|GenBank accession number||BC000097|
|Gene ID (NCBI)||7045|
|Purification Method||Caprylic acid/ammonium sulfate precipitation|
|Storage Buffer||PBS with 0.1% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
TGFBI, also named as BIGH3, Kerato-epithelin and RGD-CAP, binds to type I, II, and IV collagens. TGFBI is an adhesion protein which may play an important role in cell-collagen interactions. In cartilage, it may be involved in endochondral bone formation. TGFBI is an extracellular matrix adaptor protein, it has been reported to be differentially expressed in transformed tissues. TGFBI is a predictive factor of the response to chemotherapy, and suggest the use of TGFBI-derived peptides as possible therapeutic adjuvants for the enhancement of responses to chemotherapy.(PMID:20509890) Defects in TGFBI are the cause of epithelial basement membrane corneal dystrophy (EBMD). Defects in TGFBI are the cause of corneal dystrophy Groenouw type 1 (CDGG1). Defects in TGFBI are the cause of corneal dystrophy lattice type 1 (CDL1). Defects in TGFBI are a cause of corneal dystrophy Thiel-Behnke type (CDTB). Defects in TGFBI are the cause of Reis-Buecklers corneal dystrophy (CDRB). Defects in TGFBI are the cause of lattice corneal dystrophy type 3A (CDL3A). Defects in TGFBI are the cause of Avellino corneal dystrophy (ACD).
|Product Specific Protocols|
|WB protocol for TGFBI / BIGH3 antibody 60007-1-Ig||Download protocol|
|IHC protocol for TGFBI / BIGH3 antibody 60007-1-Ig||Download protocol|
|IF protocol for TGFBI / BIGH3 antibody 60007-1-Ig||Download protocol|
|IP protocol for TGFBI / BIGH3 antibody 60007-1-Ig||Download protocol|
|Click here to view our Standard Protocols|
TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer.
Int J Cancer
Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells.
Cell Mol Life Sci
TGFbeta-induced protein mediates lymphatic endothelial cell adhesion to the extracellular matrix under low oxygen conditions.
Identification of Hub Genes Associated With Sensitivity of 5-Fluorouracil Based Chemotherapy for Colorectal Cancer by Integrated Bioinformatics Analysis.
BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.
Absence of Vitamin K-Dependent γ-Carboxylation in Human Periostin Extracted from Fibrotic Lung or Secreted from a Cell Line Engineered to Optimize γ-Carboxylation.